Sana Biotechnology, Inc., a biotechnology company, focuses on utilizing engineered cells as medicines. The company develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system disorders, cardiovascular diseases, genetic disorders, and others. Its product candidates include SG295 and SG242 that target CD19+ cancer cells, including non-Hodgkin Lymphoma, chronic lymphocytic leukemia, and acute lymphoblastic leukemia; SG221 and SG239 for the treatment of multiple myeloma; and SG328 for ornithine transcarbamylase deficiency. It also develops SG418 for sickle cell disease and beta-thalassemia; SC291, a CD19 allogeneic T cell therapy; SC255 for multiple myeloma; SC451 for type I diabetes mellitus; and SC379 for secondary progressive multiple sclerosis, Pelizaeus-Merzbacher disease, and Huntington's disease. Sana Biotechnology, Inc. was formerly known as FD Therapeutics, Inc. and changed its name to Sana Biotechnology, Inc. in September 2018. The company was incorporated in 2018 and is headquartered in Seattle, Washington.

Sana Biotechnology, Inc.

Sana Biotechnology is focused on utilizing engineered cells as medicines for patients. The ability to modify genes and use cells as medicines will be one of the most important advances in healthcare over the next several decades.  Sana is building differentiated capabilities across the spectrum of cell and gene therapy. 
 
Three aspirations drive Sana as we look to discover treatments for patients with poor outcomes or currently untreatable diseases. The first is the ability to repair and control the genes in any cell in the body.  We are advancing novel delivery technologies with the goal of being able to deliver any payload to any cell in a specific, predictable, and repeatable manner, paving the way for next-generation in vivo gene therapy. Next is the ability to differentiate pluripotent stem cells ex vivo into immune-cloaked functional cells with the aspiration of being able to replace any missing or damaged cells in the body. Last is a belief we can enable broader access to our therapies through focusing on scalable manufacturing solutions, the cost of manufacturing, and aligning with key stakeholders.
 
Sana launched in early 2019 and has over 350 employees in Seattle, Cambridge, and South San Francisco. Sana was founded with the long view – bringing together great people and the best technologies to deliver on the challenging promise of using engineered cells to meaningfully change the outcome of many human diseases.

Over 8 million people worldwide are currently living with type 1 diabetes. At Sana, we’re advancing our hypoimmune platform for the potential treatment of this and other serious diseases. 

Check out The Economist article below highlighting promising preclinical diabetes data using our hypoimmune technology that were recently published in Cell Stem Cell.

https://lnkd.in/gRcYJtY9

Cancer prevention awareness is a key step towards a healthier future. Together, let's inspire change, promote healthy lifestyles, and drive advancements in cancer innovation to prevent and treat cancer. 

Learn more about cancer prevention here: https://lnkd.in/gT2vd6hZ

#CancerPrevention #BiotechInnovation #Cellengineering #CellTherapy

We are excited to share the publication of preclinical diabetes data in Cell Stem Cell. 
 
Published data demonstrate that transplantation of Sana’s engineered allogeneic, hypoimmune (HIP)-modified pancreatic islet cells provided lasting glucose control, enabling the achievement of exogenous insulin independence without immunosuppression in a diabetic non-human primate (NHP). 
 
These data underscore the diverse and vast potential of the hypoimmune platform to transform the diabetes treatment landscape and beyond. 
 
Read more here: https://lnkd.in/g589pFsJ

Today we announced the closing of an upsized $189M public offering. 
 
We would like to recognize the tremendous support from healthcare investors, as well as the significant interest from scientific and healthcare communities, as we collectively work to change the possible for patients. 

Read more here: https://lnkd.in/gmX_ZVnV

At Sana, we recognize first-hand the vital role women play in driving innovation and shaping the future of science and medicine. 

We are committed to continuing to break barriers, inspire the next generation, and build a more inclusive and diverse scientific community. 

#WomenInScience #GirlsInScience #BiotechInnovation #STEMdiversity

Sana welcomes the Year of the Wood Dragon, a revered symbol in Chinese culture embodying growth, prosperity, and good fortune. 

We Look forward to a year filled with creativity, innovation, and abundant opportunities. #LunarNewYear

At Sana, our focus on changing the possible for patients through engineered cells is matched by our commitment to bring awareness to cancer prevention and early detection. 

Join us in fostering awareness, driving innovation, and uniting against cancer. Together, we can make strides in both treatment and prevention. 
 
#WorldCancerDay #CellTherapy #CancerPrevention #EarlyDetection

Sana will be honoring Black History Month throughout the month of February through various events within our community. 

The Sana Pledge is a commitment to ending inequality for all, and a meaningful part of our effort is directed toward countering racism and supporting the Black community.

"The future never just happened. It was created." -- Mae Jemison

#BlackHistoryMonth

We are honored for another feature in BioSpace’s annual Hotbed Maps, representing the most thriving life science regions across the country. With three primary office locations, Sana will be featured in the #BioForest, #BiotechBay, and #Genetown maps. 

In each of our locations, employees are relentless in discovering therapies that shift the possible for patients. 

Learn more about Sana, our culture, and open positions here: https://sana.com/join-us/

#hiring #jobsatSana

Today we memorialize the millions of lives lost and honor those who survived the acts of the Holocaust. We must stand united against hatred and intolerance, ensuring such atrocities never happen again.
 
#HolocaustRemembranceDay

	Dec '18	Dec '19	Dec '20	Dec '21	Dec '22	Dec '23
average inventory
average payables		144.50K -	1.13M 679.58%	2.24M 98.49%	2.54M 13.51%	3.48M 37.21%
average receivables
book value per share		-1.09 -	-2.40 119.56%	4.38 282.20%	2.65 39.43%	1.48 44.25%
capex per share		-0.20 -	-0.14 32.25%	-0.18 31.77%	-0.11 38.22%	-0.10 7.10%
capex to depreciation		-14.34 -	-4.03 71.88%	-2.70 33.09%	-1.34 50.47%	-0.65 51.42%
capex to operating cash flow		0.31 -	0.17 43.50%	0.12 31.25%	0.07 39.49%	0.08 9.76%
capex to revenue
cash per share		1.07 -	3.80 255.77%	3.31 12.78%	2.25 32.01%	1.07 52.27%
days of inventory on hand
days payables outstanding						48.58 -
days sales outstanding
debt to assets		0.12 -	0.10 15.09%	0.10 0.24%	0.13 33.95%	0.18 39.95%
debt to equity		-0.34 -	-0.17 49.52%	0.15 189.20%	0.22 42.36%	0.36 67.00%
dividend yield
earnings yield		-0.03 -	-0.05 58.31%	-0.13 195.03%	-0.36 168.03%	-0.36 0.34%
enterprise value	-30.63M -	4.54B 14,923.83%	5.81B 28.03%	2.43B 58.13%	675.45M 72.25%	760.47M 12.59%
enterprise value over ebitda		-32.59 -	-20.32 37.66%	-6.82 66.43%	-2.48 63.67%	-2.58 4.05%
ev to operating cash flow		-53.10 -	-42.13 20.66%	-9.70 76.99%	-2.33 75.98%	-3.00 28.78%
ev to sales
free cash flow per share		-0.86 -	-0.92 7.68%	-1.69 82.82%	-1.65 2.19%	-1.41 14.80%
free cash flow yield		-0.02 -	-0.03 7.68%	-0.11 314.54%	-0.42 283.30%	-0.34 17.52%
graham net net		-3.22 -	-2.77 13.86%	0.90 132.53%	0.53 40.80%	-0.35 166.21%
graham number		4.97 -	9.27 86.44%	14.27 53.97%	9.19 35.64%	6.96 24.25%
income quality		0.65 -	0.48 26.03%	0.71 45.85%	1.08 52.60%	0.90 16.83%
intangibles to total assets	0 -	0.48 Infinity%	0.27 43.08%	0.18 35.34%	0.24 37.28%	0.35 45.54%
interest coverage					17.44 -
interest debt per share		0.37 -	0.41 10.84%	0.67 62.52%	0.49 26.22%	0.54 8.80%
inventory turnover
invested capital		-0.34 -	-0.17 49.52%	0.15 189.20%	0.22 42.36%	0.36 67.00%
market cap		4.57B -	6.15B 34.58%	2.58B 58.13%	743.96M 71.12%	793.73M 6.69%
net current asset value	-14.93M -	-413.98M 2,673.72%	-767.01M 85.28%	157.20M 120.49%	121.03M 23.01%	-64.28M 153.11%
net debt to ebitda		0.23 -	1.19 420.34%	0.40 66.50%	0.25 36.86%	0.11 55.15%
net income per share		-1.00 -	-1.59 58.31%	-2.07 30.12%	-1.41 31.61%	-1.46 2.94%
operating cash flow per share		-0.66 -	-0.79 19.91%	-1.51 91.66%	-1.54 2.09%	-1.30 15.36%
payables turnover						7.51 -
receivables turnover
research and ddevelopement to revenue
return on tangible assets		-0.61 -	-0.53 13.29%	-0.37 29.51%	-0.43 15.50%	-0.78 81.23%
revenue per share
roe		0.92 -	0.66 27.89%	-0.47 171.42%	-0.53 12.92%	-0.99 84.67%
roic		2.89 -	1.01 65.17%	-0.36 136.04%	-0.38 3.65%	-0.68 79.39%
sales general and administrative to revenue
shareholders equity per share		-1.09 -	-2.40 119.56%	4.38 282.20%	2.65 39.43%	1.48 44.25%
stock based compensation to revenue
tangible asset value	-13.19M -	-342.36M 2,496.03%	-621.01M 81.39%	528.68M 185.13%	299.49M 43.35%	87.68M 70.72%
tangible book value per share		-2.63 -	-3.54 34.78%	3.18 189.68%	1.59 49.94%	0.45 71.66%
working capital	30.81M -	124.43M 303.86%	353.02M 183.70%	458.87M 29.98%	332.93M 27.44%	149.03M 55.24%

NASDAQ:SANA

Sana Biotechnology, Inc.

Last Close

6.05

26/07 20:00

Market Cap

1.15B

Beta: 0.62

Volume Today

1.34M

Avg: 1.19M

PE Ratio

−4.34

PFCF: −4.09

Preview